This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

The FDA's controversial rejection of a skin cancer therapy from Replimune Group has prompted Krystal Biotech to shut down of ...

Neuroscientists have long held that the brain reorganizes itself when a body part is amputated. A new study says that’s not ...

Soleno Therapeutics CEO responds to a 415-page short-seller report alleging safety issues tied to the company's newly ...

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic condition, hereditary angioedema.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

Correa and Bergman are co-chairs of the congressional Psychedelics Advancing Therapies (PATH) Caucus. Mercer is a Marine ...

Morning. Today, we see fallout from the FDA’s rejection of Replimune’s melanoma drug affecting another biotech, learn how Sarepta’s decision-making has affected a patient population that hasn’t always ...

Provide your payment details. The free trial associated with this subscription will be appended to the standard duration of ...

New additions introduced by Faulkner and others include an AI scribe powered by Microsoft to rival products from health tech ...

The FDA has agreed to speed up a review of a rare disease drug developed by Stealth BioTherapeutics, a notable step after the company said it may have to close its doors otherwise.

Good morning. We've got a meaty issue for you today. In particular, I urge you to spend some time with Jason Mast's story. It's another heartbreaking ...